Angel De Jesus Corria Osorio

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


4 publications

2024 | 2023 | 2022 | 2020 |
2024
 
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J., Barras D., Pétremand R., Orcurto A., Bobisse S., Arnaud M., Auger A., Rodrigo B.N., Ghisoni E., Sauvage C. et al., 2024/09/10. Immunity, 57 (10) pp. 2466-2482. Peer-reviewed.
[DOI][Pmid][serval:BIB_3BC38E07E916]
2023
 
Generation of a novel synthetic CD8<sup>+</sup> T cell state that leads to tumor control in mice.
Corria-Osorio J., Coukos G., 2023/05. Nature immunology, 24 (5) pp. 755-756. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B121C8D85A4]
2022
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2020
 
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G., Gainza P., Gray-Gaillard E., Cribioli E., Shui S., Kim S., Kwak M.J., Vollers S., Corria Osorio A.J., Reichenbach P. et al., 2020/04. Nature biotechnology, 38 (4) pp. 426-432. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EBAD72E3D84D]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University